440 Participants Needed

Hera System for Infertility

(LOTUS Trial)

Recruiting at 6 trial locations
VS
Overseen ByVaishali Suraj, MS
Age: 18 - 65
Sex: Female
Trial Phase: Academic
Sponsor: Alife Health
Stay on Your Current MedsYou can continue your current medications while participating
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

This trial aims to see if using the Hera System can improve pregnancy rates in patients undergoing fertility treatments. The system helps embryologists choose the best embryos by providing extra information, potentially increasing the chances of pregnancy.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Eligibility Criteria

This trial is for women aged 21-43 undergoing in vitro fertilization with their own eggs, who have retrieved at least 8 eggs and are planning a single embryo transfer. They must be willing to follow the study's rules and speak English. Those using donor sperm are eligible, but not those using surgically removed sperm or donor eggs, intending to bank embryos, having cancer history, or aiming for gender selection.

Inclusion Criteria

Women undergoing in vitro fertilization treatment using their own eggs
At least 8 eggs retrieved
Single embryo transfer (SET)
See 4 more

Exclusion Criteria

Gestational carriers
Fertilization using surgically removed sperm
Concurrent participation in another clinical study that might interfere with the study results in either study
See 5 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Embryos are evaluated using the Hera System alongside traditional morphology grading to determine suitability for transfer

8 weeks
Regular visits as per embryology lab schedule

Follow-up

Participants are monitored for clinical pregnancy, defined as a fetal heartbeat at 6-8 weeks

8 weeks

Treatment Details

Interventions

  • Hera Score
Trial OverviewThe trial is testing the Hera System as an additional method alongside traditional morphological grading of embryos suitable for transfer in IVF treatments. It aims to compare pregnancy rates (confirmed by fetal heartbeat) when using this system versus standard criteria used by embryologists alone.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Device: Hera SystemExperimental Treatment1 Intervention
For the Hera, the embryologist will use the consider both the standard morphology grade and the Hera System score on embryos that were already deemed suitable for transfer or freeze based on the standard morphology assessment to determine the most suitable embryo for transfer.
Group II: Traditional MorphologyActive Control1 Intervention
The embryo selection will be based on standard of care traditional morphology only.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Alife Health

Lead Sponsor

Trials
1
Recruited
440+